Every BioFlex vial includes a QR code linking to full compound education — mechanism, dosing research, and reconstitution protocol. No guessing. No middlemen.
Each compound ships with a vial-label QR code linking to full education pages.
Every vial ships with a scannable QR code that links directly to a full compound education page — built to educate, not to confuse.
Each vial is labeled with compound name, concentration, lot number, and a printed QR code tied to that specific compound's education page.
Point any smartphone camera at the label. It instantly opens the BioFlex compound page — no app needed.
Full breakdown: what the peptide is, its mechanism of action, research-based dosing data, reconstitution protocol, and storage guidance.
No forums. No guesswork. Just clean, sourced research information accessible from the moment you open the package.
Scan with your phone camera to see exactly what your customers see when they scan their vial.
Retatrutide (LY3437943) is an investigational triple receptor agonist that simultaneously activates GLP-1, GIP, and glucagon receptors — producing some of the most dramatic body composition changes observed in clinical peptide research to date.
Phase 2 trials published in the New England Journal of Medicine (2023) showed up to 24.2% body weight reduction at 48 weeks at the 12 mg dose — surpassing tirzepatide and semaglutide in comparable timeframes.
GLP-1 reduces appetite and slows gastric emptying. GIP enhances insulin secretion and improves fat storage signaling. Glucagon increases hepatic glucose output and drives fat oxidation and thermogenesis. The triple-agonist combination produces synergistic, additive metabolic impact across all three pathways simultaneously.
Escalation protocol: increase by 0.5–1 mg every 4 weeks based on tolerance. Three arms studied in phase 2: 4 mg, 8 mg, 12 mg weekly.
Common research-reported side effects at higher doses: nausea, reduced appetite, mild GI discomfort. These are consistent with GLP-1 class compounds. All dosing figures are sourced from published clinical literature only.
Store lyophilized powder at 2–8°C in refrigerator. Stable up to 24 months under proper conditions. Can tolerate short-term room temperature transit (24–48 hrs) without significant degradation.
Store reconstituted solution refrigerated at 2–8°C. Use within 28 days. Avoid freeze-thaw cycles. Keep away from direct light. Do not use if solution appears cloudy, discolored, or contains visible particulates.
BioFlex Research was built on a simple premise: the peptide industry has a trust problem. Most companies ship vials with minimal labeling and zero education — leaving researchers to piece together information from unreliable forums and inconsistent sources.
We changed that. Every compound we supply comes with our QR Education System — a scannable code on every vial that links to a clean, sourced compound profile covering mechanism of action, clinical research data, reconstitution protocol, dosing reference, and storage guidelines.
All compounds verified for purity and concentration by independent laboratory analysis.
All education content is sourced from peer-reviewed clinical literature and published trial data.
The only peptide supplier with a full compound education system built directly into vial labeling.
We work with licensed researchers, clinics, and institutions. Reach out to discuss compound availability, bulk pricing, or custom labeling.